213 related articles for article (PubMed ID: 11686017)
21. [Chemotherapy guidelines in human cancer].
Kwaśniewska-Rokicińska C
Postepy Hig Med Dosw; 1976; 30(1):93-120. PubMed ID: 768945
[No Abstract] [Full Text] [Related]
22. Src continues aging: current and future clinical directions.
Kopetz S; Shah AN; Gallick GE
Clin Cancer Res; 2007 Dec; 13(24):7232-6. PubMed ID: 18094400
[TBL] [Abstract][Full Text] [Related]
23. Histone deacetylases and cancer: causes and therapies.
Marks P; Rifkind RA; Richon VM; Breslow R; Miller T; Kelly WK
Nat Rev Cancer; 2001 Dec; 1(3):194-202. PubMed ID: 11902574
[TBL] [Abstract][Full Text] [Related]
24. Basic cancer chemotherapy: experimental models--strategy.
Mulder JH
Cancer Clin Trials; 1978; 1(2):129-34. PubMed ID: 391424
[No Abstract] [Full Text] [Related]
25. HDAC inhibitors for the treatment of cancer.
Secrist JP; Zhou X; Richon VM
Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
[TBL] [Abstract][Full Text] [Related]
26. Histone deacetylase inhibitors: from bench to clinic.
Paris M; Porcelloni M; Binaschi M; Fattori D
J Med Chem; 2008 Mar; 51(6):1505-29. PubMed ID: 18247554
[No Abstract] [Full Text] [Related]
27. Advances in cancer management--an essay on the application of basic science principles.
Costanzi JJ
Tex Rep Biol Med; 1979; 38():79-85. PubMed ID: 394379
[No Abstract] [Full Text] [Related]
28. New nucleoside analogues in clinical development.
Faderl S; Gandhi V; Kantarjian H; Plunkett W
Cancer Chemother Biol Response Modif; 2002; 20():37-58. PubMed ID: 12703199
[No Abstract] [Full Text] [Related]
29. Imatinib as a paradigm of targeted therapies.
Druker BJ
Adv Cancer Res; 2004; 91():1-30. PubMed ID: 15327887
[TBL] [Abstract][Full Text] [Related]
30. Topoisomerase I interactive agents.
Stewart CF
Cancer Chemother Biol Response Modif; 2001; 19():85-128. PubMed ID: 11686040
[TBL] [Abstract][Full Text] [Related]
31. Stopping the spread of cancer.
Ewan S
Drug Discov Today; 2005 Feb; 10(3):162-3. PubMed ID: 15708525
[No Abstract] [Full Text] [Related]
32. Rational combinations using HDAC inhibitors.
Bots M; Johnstone RW
Clin Cancer Res; 2009 Jun; 15(12):3970-7. PubMed ID: 19509171
[TBL] [Abstract][Full Text] [Related]
33. Diflomotecan. Ipsen.
Osheroff N
IDrugs; 2004 Mar; 7(3):257-63. PubMed ID: 15011101
[No Abstract] [Full Text] [Related]
34. Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations.
Brunner TB; Hahn SM; Gupta AK; Muschel RJ; McKenna WG; Bernhard EJ
Cancer Res; 2003 Sep; 63(18):5656-68. PubMed ID: 14522880
[TBL] [Abstract][Full Text] [Related]
35. Deal watch: Bristol-Myers Squibb and Exelixis collaborate on kinase inhibitors.
Nat Rev Drug Discov; 2009 Feb; 8(2):98. PubMed ID: 19180098
[No Abstract] [Full Text] [Related]
36. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
Carew JS; Giles FJ; Nawrocki ST
Cancer Lett; 2008 Sep; 269(1):7-17. PubMed ID: 18462867
[TBL] [Abstract][Full Text] [Related]
37. Telomerase inhibition, oligonucleotides, and clinical trials.
Corey DR
Oncogene; 2002 Jan; 21(4):631-7. PubMed ID: 11850789
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy.
Piekarz RL; Sackett DL; Bates SE
Cancer J; 2007; 13(1):30-9. PubMed ID: 17464244
[TBL] [Abstract][Full Text] [Related]
39. Histone deacetylase inhibitors: overview and perspectives.
Dokmanovic M; Clarke C; Marks PA
Mol Cancer Res; 2007 Oct; 5(10):981-9. PubMed ID: 17951399
[TBL] [Abstract][Full Text] [Related]
40. New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspective.
Awada A; Mano M; Hendlisz A; Piccart M
Expert Rev Anticancer Ther; 2004 Feb; 4(1):53-60. PubMed ID: 14748657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
